Table 4. Multivariable-adjusted association between statin use after diagnosis with pancreatic cancer and overall survival in substrata of covariates.

Variables	Category	Adjusted HR (95% CI) for death comparing statin use vs. non-use	p-value	P-value for interaction
Age				0.86
	65–74	0.94 (0.85, 1.04)	0.23
	75–84	0.93 (0.84, 1.03)	0.15
	85+	0.96 (0.81, 1.15)	0.68
Summary stage				0.34
	Localized/Regional	0.91 (0.82, 1.00)	0.051
	Distant	0.99 (0.90, 1.08)	0.75
Grade				0.02
	1 or 2	0.79 (0.67, 0.93)	0.004
	3 or 4	1.07 (0.89, 1.29)	0.45
Tumor size				0.38
	<5cm	0.94 (0.86, 1.02)	0.14
	≥5cm	0.88 (0.75, 1.03)	0.11
Resection				0.054
	Yes	0.80 (0.66, 0.97)	0.02
	No	0.96 (0.90, 1.03)	0.26
Chemotherapy				0.72
	Yes	0.93 (0.82, 1.04)	0.21
	No	0.96 (0.88, 1.03)	0.25
Dyslipidemia				0.52
	Yes	0.95 (0.88, 1.03)	0.24
	No	0.95 (0.84, 1.07)	0.41
Diabetes/IGT				0.99
	Yes	0.92 (0.84, 1.02)	0.1
	No	0.95 (0.97, 1.04)	0.25
Chronic pancreatitis				0.03
	Yes	0.75 (0.56, 0.99)	0.04
	No	0.96 (0.90, 1.03)	0.15
COPD				0.07
	Yes	0.89 (0.80, 1.00)	0.046
	No	0.98 (0.91, 1.06)	0.66
Statin use pre cancer diagnosis				0.11
	Yes	0.97 (0.84, 1.11)	0.65
	No	0.80 (0.63, 1.00)	0.048
.

Note: Stratified analysis in which statistically significant associations of statin use after cancer diagnosis with survival are highlighted in bold type